The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
JARDIANCE (Boehringer Ingelheim Pty Ltd)
Product name
JARDIANCE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
211 (255 working days)
Active ingredients
empagliflozin
Registration type
EOI
Indication
Heart failure
JARDIANCE is indicated in adults for the treatment of symptomatic heart failure independent of left ventricular ejection fraction, as an adjunct to standard of care therapy (see Section 5.1 Pharmacodynamic properties - Clinical trials).